Resources

This blog explores the key investor insights, policy priorities, and technological breakthroughs shaping the future of UK TechBio, revealing how collaboration, talent, and data are driving the sector from innovation to global endurance.

Thermo Fisher Scientific Inc. announced a definitive agreement to acquire Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, from a shareholder group led by Astorg and Nordic Capital, Novo Holding and Cinven, for $8.875 billion.

Research shows that while 85% of biopharma executives view partnerships as business-critical, around half report failure rates exceeding 60%. Baringa is on a mission to help life sciences organisations get partnering right, and in this episode, listeners hear how CRH navigates these challenges to accelerate innovation and deliver transformative therapies to patients.

Clinical trial results on drug free obesity treatment, published in peer reviewed journal, Obesity. Commercial launch in UK first, planned for 2027.

The UK biotech financing numbers for Q3 are out, showing validation of UK assets but a sector under strain from prolonged global headwinds. Time to double down on investment in innovation as a driver for growth and deploy Industrial Strategy plans with urgency.

LifeArc and the Gates Foundation are funding seven ground-breaking new projects launched to lower the cost of monoclonal antibody production to make them more accessible globally.

New BIA data shows venture capital activity slowing amid the longest global funding drought in the sector. Despite a landmark M&A deal validating UK science, the figures signal a fragile moment that needs urgent government action.

From scaling up advanced therapy manufacturing to harnessing the power of digital and automation, Ed Samuel, the new COO of the CGT Catapult, discusses how collaboration and innovation will shape the next phase of the UK’s cell and gene therapy ecosystem.

Last week, the Teesside business community and local guests came together at Wilton Centre, near Redcar, to commemorate the 50th anniversary of the iconic research space, a renowned landmark in Europe’s R&D landscape.

NRG announced the expansion of its team with the addition of three senior appointments in newly created roles: Sarah Almond as VP of Translational Biology; David Brocklebank as Director of Clinical Operations; and Kathryn Oliver as Director of Project Management.

Coulter Partners completed a search assignment for Tristel plc (AIM: TSTL) and is pleased to announce the placement of Anna Wasyl as Chief Financial Officer.

Dr Graham Spittle CBE has been appointed as the new Chair of Trustees at the Rosalind Franklin Institute from November 2025.

Medannex Ltd (Edinburgh) announced the presentation of the first clinical data from the ongoing Phase 1b study of MDX-124, at the European Society for Medical Oncology (ESMO) Congress 2025.

​​​​​​​Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.

Results from a US multicenter study presented at CHEST show e-Lung could have sped up Progressive Pulmonary Fibrosis (PPF) diagnosis by up to 21 months

Cyclana Bio announced the close of a £5 million pre-seed funding round, co-led by NfX and Eka VC, and including Cocoa VC, Wilbe, and Angel investors.

A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.

In this blog, Justin Wilson, Withers & Rogers LLP, shares his expert perspective on what the recent patent rulings from the Unified Patent Court (UPC) and the Court of Justice of the European Union (CJEU) mean in practice for biotech and pharma companies.